



Work Group Considerations: Proposed Recommendation Text for Policy Options

Mary Choi, MD, MPH

Viral Special Pathogens Branch
Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices

February 26, 2020

1st Vaccination Policy Issue for Consideration Today

Vaccination of healthy, non-pregnant, non-lactating adults \geq 18 years of age

Should pre-exposure vaccination with the rVSV Δ G-ZEBOV-GP vaccine be recommended for individuals in the U.S. population responding to an outbreak of Ebola virus disease due to Ebola virus (species *Zaire ebolavirus*)?

1st Vaccination Policy Issue for Consideration Today

Vaccination of healthy, non-pregnant, non-lactating adults \geq 18 years of age

Should pre-exposure vaccination with the rVSV Δ G-ZEBOV-GP vaccine be recommended for individuals in the U.S. population responding to an outbreak of Ebola virus disease due to Ebola virus (species *Zaire ebolavirus*)?

WG proposal by strong majority: Recommend

Reasoning for “Recommend” Proposal: Individuals responding to an outbreak of EVD

- Documented history of infections in outbreak responders
- Benefits of vaccination outweigh the risk
 - Severe disease
 - No FDA-approved treatment
- Risk of exposure even with appropriate use of personal protective equipment

Proposed Text: 1st Vaccination Policy Issue for Consideration Today

Pre-exposure vaccination with rVSVΔG-ZEBOV-GP vaccine is recommended for healthy, non-pregnant, non-lactating adults 18 years of age or older in the U.S. population who are responding to an outbreak of Ebola virus disease and are at potential risk for exposure to Ebola virus (species *Zaire ebolavirus*)

2nd Vaccination Policy Issue for Consideration Today

Vaccination of healthy, non-pregnant, non-lactating adults \geq 18 years of age

Should pre-exposure vaccination with the rVSV Δ G-ZEBOV-GP vaccine be recommended for healthcare personnel* involved in the care and transport of confirmed Ebola virus disease patients at federally-designated Ebola Treatment Centers in the United States?

2nd Vaccination Policy Issue for Consideration Today

Vaccination of healthy, non-pregnant, non-lactating adults \geq 18 years of age

Should pre-exposure vaccination with the rVSV Δ G-ZEBOV-GP vaccine be recommended for healthcare personnel* involved in the care and transport of confirmed Ebola virus disease patients at federally-designated Ebola Treatment Centers in the United States?

WG proposal by strong majority: Recommend

Reasoning for “Recommend” Proposal: HCP* at U.S. Federally-Designated Ebola Treatment Centers

- Operational ETCs with trained and vaccinated personnel is a part of public health preparedness
- Population is at high-risk of occupational exposure to the virus
- Provides an added layer of protection, in addition to other biosafety measures (e.g., personal protective equipment, engineering controls etc.)

Proposed Text: 2nd Vaccination Policy Issue for Consideration Today

Pre-exposure vaccination with rVSVΔG-ZEBOV-GP vaccine is recommended for healthy, non-pregnant, non-lactating adults 18 years of age or older who work as healthcare personnel¹ at a federally-designated Ebola Treatment Center in the United States who are at potential risk for exposure to Ebola virus (species *Zaire ebolavirus*)

3rd Vaccination Policy Issue for Consideration Today

Vaccination of healthy, non-pregnant, non-lactating adults \geq 18 years of age

Should pre-exposure vaccination with the rVSV Δ G-ZEBOV-GP vaccine be recommended for laboratorians and support staff at biosafety-level 4 facilities that handle replication-competent Ebola virus (species *Zaire ebolavirus*) in the United States

3rd Vaccination Policy Issue for Consideration Today

Vaccination of healthy, non-pregnant, non-lactating adults \geq 18 years of age

Should pre-exposure vaccination with the rVSV Δ G-ZEBOV-GP vaccine be recommended for laboratorians and support staff at biosafety-level 4 facilities that handle replication-competent Ebola virus (species *Zaire ebolavirus*) in the United States

WG proposal by strong majority : Recommend

Reasoning for “Recommend”: BSL-4 Laboratorians and Support Staff

- Population at high risk for occupational exposure
- Provides an added layer of protection, in addition to other biosafety measures (e.g., personal protective equipment, engineering controls etc.)

Proposed Text: 3rd Vaccination Policy Issue for Consideration Today

Pre-exposure vaccination with rVSVΔG-ZEBOV-GP vaccine is recommended for healthy, non-pregnant, non-lactating adults 18 years of age or older who work as laboratorians and support staff at biosafety-level 4 facilities in the U.S. who are at potential risk for exposure to Ebola virus (species *Zaire ebolavirus*)

Healthcare Personnel Definition

- 1 Healthcare personnel (HCP) refers to all paid and unpaid persons serving in healthcare settings who have the potential for direct or indirect exposure to patients or infectious materials, including body substances (e.g., blood, tissue, and specific body fluids); contaminated medical supplies, devices, and equipment; contaminated environmental surfaces; or contaminated air. These HCP include, but are not limited to, emergency medical service personnel, nurses, nursing assistants, physicians, technicians, *clinical laboratory personnel*, *autopsy personnel*, therapists, phlebotomists, pharmacists, students and trainees, contractual staff not employed by the healthcare facility, and persons not directly involved in patient care, but who could be exposed to infectious agents that can be transmitted in the healthcare setting (e.g., clerical, dietary, environmental services, laundry, security, engineering and facilities management, administrative, billing, and volunteer personnel).

Adapted from <https://www.cdc.gov/infectioncontrol/guidelines/healthcare-personnel/index.html>

Ebola Vaccine ACIP Work Group

ACIP Members

Sharon Frey (Chair)

Beth Bell

Robert Atmar

Ex Officio Members

Rebecca Reindel (FDA)

Stephanie Polo (FDA)

Eric Deussing (DOD)

Amanda Zarrabian (BARDA)

Dan Wolfe (BARDA)

Elizabeth Higgs (NIH)

Richard Davey (NIH)

John Redd (ASPR)

CDC Lead

Mary Choi

Liaison Representatives

Alexander Isakov (ACEP)

Laura Riley (ACOG)

Sandra Adamson Fryhofer (AMA)

Christine Hahn (CSTE)

Milan Patel (NACI)

Chris Nyquist (AAP)

Daniel Lucey (IDSA)

David Weber (SHEA)

Consultants

Collen Kraft (Emory University)

Jim LeDuc (UTMB)

Pierre Rollin

Allison Liddell (Texas Health Dallas)

Armand Sprecher (MSF)

Stacy Hall (AIM)

Grade Consultants/CDC Contributors

GRADE Consultants

Rebecca Morgan

Doug Campos-Outcalt

CDC Contributors

Caitlin Cossaboom

Amy Whitesell

Jonathan Dyal

Allison Joyce

Susan Gorman

Jessica MacNeil

Sarah Mbaeyi

Marissa Person

Brian Harcourt

Terri Hyde

Rita Helfand

Yon Yu

Susan Goldstein

Inger Damon

Susan Gorman

Michael Bell

Shah Roohi

Julianne Gee

Jennifer McQuiston

Elizabeth Ervin

John Su

Joel Montgomery

Trevor Shoemaker

Julie Villanueva

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Vote

Language for Vote

Pre-exposure vaccination with rVSVΔG-ZEBOV-GP vaccine is recommended for adults 18 years of age or older in the U.S. population who are at potential risk of exposure to Ebola virus (species *Zaire ebolavirus*) and:

- Are responding to an outbreak of Ebola virus disease; or
- Work as healthcare personnel¹ at federally-designated Ebola Treatment Centers in the United States; or
- Work as laboratorians or other staff at biosafety-level 4 facilities in the United States